+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06342544

Study of Immediate Corticosteroid Treatment and Rituximab to Prevent Muscle Weakness Spread in Ocular Myasthenia Gravis

Led by Fondation Ophtalmologique Adolphe de Rothschild · Updated on 2026-01-21

128

Participants Needed

11

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Myasthenia is an autoimmune condition that affects the connection between nerves and muscles, leading to muscle weakness that can vary over time. Many patients initially experience symptoms limited to the eye muscles, called ocular myasthenia OMG. However, in 20-40% of cases, the disease progresses to involve other muscles, which can be serious and require intensive care. This trial aims to study whether starting corticosteroid treatment immediately after diagnosis, combined with rituximab if symptoms return, can prevent the progression of ocular myasthenia to generalized disease within the first two years. Participants will be randomly assigned to receive either the usual care or a proactive treatment approach. The proactive approach includes starting corticosteroids right away at a standardized dose of 0.5 mgkgday of prednisone. If ocular symptoms recur as corticosteroids are reduced, rituximab will be added at 500 mg every 6 months for one year. The study compares this strategy against standard practice, which typically delays corticosteroid use and treats only with symptomatic medications initially. During the study, participants will be followed for two years to monitor whether their myasthenia progresses beyond the eye muscles. Researchers will assess muscle strength and symptoms using clinical evaluations and tests to measure muscle function. The main goal is to see how many patients develop generalized myasthenia during this period. Safety and tolerability of treatments will also be observed, with ongoing monitoring throughout the trial duration ending in 2029.

CONDITIONS

Brief Title

Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.

Research Team

A

Antoine Gueguen

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here